137 related articles for article (PubMed ID: 33891201)
21. A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer.
Beek MA; Gobardhan PD; Klompenhouwer EG; Menke-Pluijmers MB; Steenvoorde P; Merkus JW; Rutten HJ; Voogd AC; Luiten EJ
Eur J Surg Oncol; 2020 Jan; 46(1):59-64. PubMed ID: 31402072
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a nomogram to predict the risk of breast cancer-related lymphedema among Chinese breast cancer survivors.
Liu YF; Liu JE; Zhu Y; Mak YW; Qiu H; Liu LH; Yang SS; Chen SH
Support Care Cancer; 2021 Sep; 29(9):5435-5445. PubMed ID: 33704565
[TBL] [Abstract][Full Text] [Related]
23. A Prospective Study to Assess the Feasibility of Axillary Reverse Mapping and Evaluate Its Effect on Preventing Lymphedema in Breast Cancer Patients.
Yue T; Zhuang D; Zhou P; Zheng L; Fan Z; Zhu J; Hou L; Yu F; Dong X; Xiao L; He Q
Clin Breast Cancer; 2015 Aug; 15(4):301-6. PubMed ID: 25776198
[TBL] [Abstract][Full Text] [Related]
24. Axillary reverse mapping: Is it feasible in locally advanced breast cancer patients?
Khandelwal R; Poovamma CU; Shilpy C; Prema M; Anthony P
Breast Dis; 2014 Jan; 34(4):151-5. PubMed ID: 24934169
[TBL] [Abstract][Full Text] [Related]
25. Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients.
Soares EW; Nagai HM; Bredt LC; da Cunha AD; Andrade RJ; Soares GV
World J Surg Oncol; 2014 Mar; 12():67. PubMed ID: 24670000
[TBL] [Abstract][Full Text] [Related]
26. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients.
Helyer LK; Varnic M; Le LW; Leong W; McCready D
Breast J; 2010; 16(1):48-54. PubMed ID: 19889169
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in breast cancer-related lymphedema of the arm: lymphatic pump failure and predisposing factors.
Stanton AW; Modi S; Mellor RH; Levick JR; Mortimer PS
Lymphat Res Biol; 2009; 7(1):29-45. PubMed ID: 19302022
[TBL] [Abstract][Full Text] [Related]
28. [Functional axillary dissection based on lymphatic drainage for breast cancer: a single center randomized clinical trial].
Yuan QQ; Hou JX; Zhou R; Zou SQ; Wu GS
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2531-2536. PubMed ID: 34407579
[No Abstract] [Full Text] [Related]
29. Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery.
Ahn SK; Kim MK; Kim J; Lee E; Yoo TK; Lee HB; Kang YJ; Kim J; Moon HG; Chang JM; Cho N; Moon WK; Park IA; Noh DY; Han W
Cancer Res Treat; 2017 Oct; 49(4):1088-1096. PubMed ID: 28161935
[TBL] [Abstract][Full Text] [Related]
30. Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong.
Mak SS; Yeo W; Lee YM; Mo KF; Tse KY; Tse SM; Ho FP; Kwan WH
Nurs Res; 2008; 57(6):416-25. PubMed ID: 19018216
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.
McLaughlin SA; Wright MJ; Morris KT; Giron GL; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
J Clin Oncol; 2008 Nov; 26(32):5213-9. PubMed ID: 18838709
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.
Yu Y; Wang Z; Wei Z; Yu B; Shen P; Yan Y; You W
BMC Cancer; 2021 Apr; 21(1):466. PubMed ID: 33902502
[TBL] [Abstract][Full Text] [Related]
33. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients?
Tausch C; Baege A; Dietrich D; Vergin I; Heuer H; Heusler RH; Rageth C
Eur J Surg Oncol; 2013 Aug; 39(8):880-6. PubMed ID: 23735162
[TBL] [Abstract][Full Text] [Related]
34. Periclavicular Lymph Node Activation Maintains the Lymphatic Circulation of Upper Extremity Following Breast Cancer Surgery with Axillary Lymph Node Dissection.
Kang SH; Lee DG
Lymphat Res Biol; 2021 Jun; 19(3):256-260. PubMed ID: 32986507
[No Abstract] [Full Text] [Related]
35. Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early Intervention.
Bucci LK; Brunelle CL; Bernstein MC; Shui AM; Gillespie TC; Roberts SA; Naoum GE; Taghian AG
Ann Surg Oncol; 2021 Dec; 28(13):8624-8633. PubMed ID: 34117574
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.
McLaughlin SA; Wright MJ; Morris KT; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
J Clin Oncol; 2008 Nov; 26(32):5220-6. PubMed ID: 18838708
[TBL] [Abstract][Full Text] [Related]
37. Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer - a long-term observation.
Rupp J; Hadamitzky C; Henkenberens C; Christiansen H; Steinmann D; Bruns F
Radiat Oncol; 2019 Mar; 14(1):39. PubMed ID: 30845971
[TBL] [Abstract][Full Text] [Related]
38. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy.
Boneti C; Korourian S; Bland K; Cox K; Adkins LL; Henry-Tillman RS; Klimberg VS
J Am Coll Surg; 2008 May; 206(5):1038-42; discussion 1042-4. PubMed ID: 18471751
[TBL] [Abstract][Full Text] [Related]
39. Upper outer boundaries of the axillary dissection. Result of the SENTIBRAS protocol: Multicentric protocol using axillary reverse mapping in breast cancer patients requiring axillary dissection.
Nos C; Clough KB; Bonnier P; Lasry S; Le Bouedec G; Flipo B; Classe JM; Missana MC; Doridot V; Giard S; Charitansky H; Charles-Nelson A; Bats AS; Ngo C
Eur J Surg Oncol; 2016 Dec; 42(12):1827-1833. PubMed ID: 27769634
[TBL] [Abstract][Full Text] [Related]
40. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
